Hikma Pharmaceuticals PLC (LON:HIK) Receives Medium “Hold” Recommendation From Analysts
Hikma Pharmaceuticals PLC (LON:HIK – Get Rating) has been given an average rating of “Hold” by the six analysts who currently cover the company, reports MarketBeat Ratings. Five research analysts rated the stock with a hold recommendation and one gave the company a buy recommendation. The average 1-year price target among brokers who updated their coverage on the stock in the past year is 2,262 GBX ($27.33).
HIK has been the subject of several research reports. Barclays reiterated an “equal weight” rating and set a price target of 1,750 GBX ($21.15) on Hikma Pharmaceuticals shares in a Wednesday, August 31 research report. JPMorgan Chase & Co. lowered its price target on Hikma Pharmaceuticals from 1,900 GBX ($22.96) to 1,760 GBX ($21.27) and set a “neutral” rating for the company in a Thursday report August 11.
Hikma Pharmaceuticals sources 1.5%
Shares of LON HIK opened at 1,285.50 GBX ($15.53) on Friday. The company’s 50-day simple moving average is 1,552.96 GBX and its 200-day simple moving average is 1,745.34 GBX. The company has a market capitalization of £2.83 billion and a price to earnings ratio of 988.85. The company has a quick ratio of 1.27, a current ratio of 2.12 and a debt ratio of 70.79. Hikma Pharmaceuticals has a 12-month low of 1,244 GBX ($15.03) and a 12-month high of 2,550.15 GBX ($30.81).
Hikma Pharmaceuticals cuts its dividend
The company also recently announced a dividend, which will be paid on Monday, September 19. Shareholders of record on Thursday August 18 will receive a dividend of $0.19 per share. The ex-dividend date is Thursday, August 18. This represents a return of 0.89%. Hikma Pharmaceuticals’ dividend payout ratio is currently 40.03%.
Hikma Pharmaceuticals Company Profile
(Get a rating)
Hikma Pharmaceuticals PLC develops, manufactures, markets and sells a range of generic, branded and licensed pharmaceutical products. The Company offers its products in solid, semi-solid, liquid and injectable final dosage forms. It operates through three segments: injectables, generics and branded.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Hikma Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Hikma Pharmaceuticals was not on the list.
While Hikma Pharmaceuticals currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here